IVVD

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on monoclonal antibody (mAb) therapies for viral diseases.

Its lead product, PEMGARDA®, is currently FDA-authorized for COVID-19 prevention in immunocompromised individuals.

As of late 2025, the company has advanced its next-generation candidate, VYD2311, into Phase 3 clinical trials with FDA Fast Track Designation, aiming to provide a long-acting vaccine alternative for the general population.